Takashi Watanabe

Takashi Watanabe, MD, PhD

Professor, Immuno-Gene Therapy, Mie University Graduate School of Medicine

Address

2-174, Edobashi, Tsu, Mie, 514-8507
Phone +59-231-5187, Fax +59-231-5276
E-mail: twatanabe@doc.medic.mie-u.ac.jp

Research Field and Profiles

Cancer Immunotherapy and Gene Therapy, and Extracellular Vesicle.
He graduated from Chiba University School of Medicine. After spending two years as a trainee at Japanese Red Cross Nagoya Daini Hospital, he belonged to Department of Hematology, and he learned bone marrow transplantation. In 1990, he moved to Tokyo to work in Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, where he was engaged in chemotherapy for patients with solid tumors. At that time, he set about to learn molecular biology at Virus Laboratory, National Children’s Medical Research Center, supervised by Dr. Shuki Mizutani. After he took a Ph.D. at First Department of Internal Medicine, Nagoya University Graduate School of Medicine in 1995, he worked as a research fellow in Department of Medicine, University of California, San Diego. Prof. Flossie Wong-Staal was his supervisor, who was conducting gene therapy by introducing ribozymes into lymphocytes from HIV patients. In 1997, he got a position as a research associate at Departments of Genetics and Experimental Surgery, Duke University Medical Center, where Dr. Bruce A Sullenger guided in his studies. In April in 2000, he got employed in National Cancer Center Hospital at Tokyo. In 2002, he was elected as First Assistant Manager of the special ward for the patients enrolled in clinical trials, especially in phase I trials in Hematology and Oncology, Gastroenterology, and Hepatobiliary Pancreatic Department. On July in 2016, he moved to Aichi Prefecture to work as Chief, Department of Hematology in Komaki City Hospital. On April, 2016, he began to work as a professor of Department of Immuno-Gene Therapy at Mie University Graduate School of Medicine.

Recent Publications

  1. Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol 5: e520-531, 2018.
  2. Sugimoto T, Watanabe T. Follicular lymphoma: the role of the tumor microenvironment in prognosis. J Clin Exp Hematop 56:1-19, 2016.
  3. Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol 172:745-756, 2016.
  4. Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M. Lipopolysaccharide-induced CXCL mRNA level and six stimulant-mRNA combinations in whole blood: novel biomarkers for bortezomib responses obtained from a prospective multicenter trial for patients with multiple myeloma. PLoS One 10:e0128662. doi:10.1371/journal.pone.0128662.
  5. Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M. Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer J Oct 4;3:e150. doi: 10.1038/bcj.2013.47.
  6. Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma: JCOG 0203 Trial. J Clin Oncol 29: 3990-3998, 2011.
  7. Watanabe T. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 19: 1113-1127, 2010.
  8. Watanabe T, Nagase K, Chosa M, Tobinai K. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer 103: 1580-1587, 2010.
  9. Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 51: 813-821, 2010.
  10. Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Maesima AM, Matsuno Y, Tobinai K. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101: 196-200, 2010.
  11. Maruyama D, Watanabe T, Heike Y, Nagase K, Takahashi N, Yamasaki S, Waki F, Yokoyama H, Kim SW, Kobayashi Y, Aizawa S, Tobinai K. Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. Int J Hematol 88: 396-402, 2008.
  12. Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Teraucui T, Nawano S, Matsusako M, Matsuno Y, NakamuraS, Mori S, Ohashi Y, Hayashi M, Serui T, Hotta T. Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin’s lymphoma. J Clin Oncol 24: 174-180, 2006.
  13. Watanabe T, Terui S, Itoh K, Terauchi T, Igarashi T, Usubuchi N, Nakata M, Nawano S, Sekiguchi N, Kusumoto S, Tanimoto K, Kobayashi Y, Endo K, Seriu T, Hayashi M, Tobinai K. Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 96: 903-910, 2005.
  14. Watanabe T, Sullenger BA. RNA repair: a novel approach to gene therapy. Advanced Drug Delivery Reviews 44: 109-118, 2000.
  15. Watanabe T, Sullenger BA. Trans-splicing ribozyme-mediated repair of tumor suppressor p53 mutant mRNAs in human cancer cells. Proc Natl Acad Sci USA 97: 8490-8494, 2000.